Merck & Co. (MRK)
(Delayed Data from NYSE)
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
Merck (MRK) Q4 Earnings & Sales Miss, CEO Frazier Steps Down
by Zacks Equity Research
Merck (MRK) misses Q4 estimates for earnings and sales. CEO Kenneth C. Frazier, to retire.
Ligand (LGND) Q4 Earnings & Sales Top, 2021 Guidance Raised
by Zacks Equity Research
Ligand (LGND) reports better-than-expected fourth-quarter 2020 numbers. The company raises outlook for 2021.
Will Merck (MRK) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
What's in the Cards for Bristol-Myers' (BMY) Q4 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter 2020 results.
Pfizer's (PFE) Key Brands Likely to Drive Its Q4 Earnings
by Zacks Equity Research
Pfizer's (PFE) Biopharma unit becomes the "New Pfizer" following the separation of the Upjohn unit. The Q4 announcement will the first quarterly result for the "New Pfizer".
Will Recovery in AbbVie's (ABBV) Earnings Continue in Q4?
by Zacks Equity Research
Recovery in AbbVie's (ABBV) revenues is likely to have continued in the fourth quarter. Investors focus is likely to be on 2021 guidance when the company reports results in the wake of rising cases.
Pharma Stock Roundup: JNJ, NVS Q4 Earnings, MRK & LLY's Coronavirus Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q4 results. Merck (MRK), AbbVie (ABBV) & Pfizer (PFE) get EU approvals.
Will Glaxo (GSK) Q4 Earnings Recover From Coronavirus Woes?
by Zacks Equity Research
Glaxo's (GSK) new and specialty products are likely to have driven fourth-quarter sales. The results will provide clarity on the impact of coronavirus on the company's vaccine business.
Eli Lilly (LLY) Q4 Earnings Top, COVID-19 Antibody Boosts Sales
by Zacks Equity Research
Lilly (LLY) beats fourth-quarter estimates for both earnings and sales. Stock up in pre-market trading.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $77.92, marking a +1.1% move from the previous day.
5 Big Pharma/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.
Wall Street Just Got Hammered: Grab 5 Ultra-Safe Stocks Now
by Tirthankar Chakraborty
With Wall Street seeing its worst one-day selloff on Jan 27 since October 2020 and with the bearish trend likely to continue, it's safe to bet on stocks like Allete (ALE), B&G Foods (BGS) and Merck (MRK).
Novartis (NVS) Misses on Q4 Earnings, Issues Grim 2021 Outlook
by Zacks Equity Research
Novartis (NVS) reports dismal fourth-quarter results as the pandemic affected sales. The outlook for 2021 also indicates challenges ahead.
Merck's (MRK) Keytruda Gets EC Nod for MSI-H Colorectal Cancer
by Zacks Equity Research
The European Commission approves Merck's (MRK) Keytruda as a monotherapy for first-line treatment of patients with metastatic MSI-H or dMMR colorectal cancer.
Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the fourth quarter.
J&J (JNJ) Q4 Earnings & Sales Beat, 2021 Guidance Upbeat
by Zacks Equity Research
J&J (JNJ) beats fourth-quarter 2020 estimates for both earnings and sales. It issues its adjusted earnings and sales outlook for 2021. Stock up.
Pfizer's (PFE) Bavencio Gets EU Nod for First-Line Bladder Cancer
by Zacks Equity Research
The European Commission approves Pfizer (PFE) and Merck KGaA's Bavencio as a monotherapy for first-line maintenance treatment in advanced/metastatic urothelial carcinoma.
Bayer (BAYRY) Gets a Boost With Product Approvals and Deals
by Zacks Equity Research
Bayer (BAYRY) gets a boost as it wins approvals for a few candidates and enters into collaboration agreements.
Will Eli Lilly (LLY) Beat Estimates This Earnings Season?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) fourth-quarter sales.
Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC
by Zacks Equity Research
Exelixis (EXEL) obtains FDA approval for Cabometyx in combination with immuno-oncology drug, Opdivo, for the first-line treatment of patients with advanced kidney cancer.
Merck (MRK) Stock Moves -0.25%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $80.98, moving -0.25% from the previous trading session.
5 Finest PEG Stocks for GARP Investors
by Urmimala Biswas
Here are five picks out of 45 top-ranked stocks with discounted PEG.
Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal
by Kinjel Shah
Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.
Bristol Myers' (BMY) Opdivo Label Expansion Gets Priority Review
by Zacks Equity Research
Bristol Myers' (BMY) sBLA for the label expansion of Opdivo for gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma gets priority review.
Merck's (MRK) Heart Failure Drug Vericiguat Gets FDA Nod
by Zacks Equity Research
Merck (MRK)/Bayer's (BAYRY) vericiguat gets FDA approval for symptomatic chronic heart failure and reduced ejection fraction